Aida Kiviniemi1, Maria Gardberg2, Paul Ek3, Janek Frantzén4, Johan Bobacka3, Heikki Minn5. 1. Department of Radiology, Division of Medical Imaging, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, FI-20521, Turku, Finland. aida.kiviniemi@utu.fi. 2. Department of Pathology, University of Turku, Turku University Hospital, Turku, Finland. 3. Johan Gadolin Process Chemistry Centre, Laboratory of Analytical Chemistry, Åbo Akademi University, Turku, Finland. 4. Department of Neurosurgery and Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland. 5. Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.
Abstract
PURPOSE: To quantitate gadolinium deposits in gliomas and adjacent normal brain specimens, and to evaluate their association with tumor contrast enhancement and the type of gadolinium-based contrast agent (GBCA) used. METHODS: A total of 69 patients with primary glioma who underwent contrast-enhanced magnetic resonance imaging (MRI) prior to surgery were included in this retrospective study. Gadolinium was measured from histologically viable tumor, normal brain, and necrosis within the sample, when available, using inductively coupled plasma mass spectrometry (ICP-MS). Tumor contrast enhancement was categorized as none, minimal, or noticeable. Differences in gadolinium deposits by contrast enhancement and GBCA type were assessed. RESULTS: Seven patients received linear GBCA and 62 macrocyclic, respectively. At the time of surgery, gadolinium deposits were detected in 39 out of 69 (57%) tumor samples, 8 out of 13 (62%) normal brain, and 12 out of 14 (86%) necrotic specimens. Gadolinium was detected in both enhancing and non-enhancing tumors, but was greatest in gliomas with noticeable enhancement (p = 0.02). Administration of linear agents gadodiamide and gadopentetate dimeglumine resulted in significantly higher tumor gadolinium relative to macrocyclic gadoterate meglumine (p < 0.01 and p < 0.05, respectively). Normal brain and necrosis also showed higher gadolinium after exposure to linear gadodiamide (both p < 0.05). In multivariate regression, GBCA type (linear/macrocyclic) was the most powerful predictor of tumor gadolinium retention (p < 0.001). CONCLUSION: Gadolinium can be detected in both enhancing and non-enhancing gliomas, neighboring normal brain, and necrosis. Gadolinium retention is higher after exposure to linear GBCAs compared with the macrocyclic gadoterate meglumine.
PURPOSE: To quantitate gadolinium deposits in gliomas and adjacent normal brain specimens, and to evaluate their association with tumor contrast enhancement and the type of gadolinium-based contrast agent (GBCA) used. METHODS: A total of 69 patients with primary glioma who underwent contrast-enhanced magnetic resonance imaging (MRI) prior to surgery were included in this retrospective study. Gadolinium was measured from histologically viable tumor, normal brain, and necrosis within the sample, when available, using inductively coupled plasma mass spectrometry (ICP-MS). Tumor contrast enhancement was categorized as none, minimal, or noticeable. Differences in gadolinium deposits by contrast enhancement and GBCA type were assessed. RESULTS: Seven patients received linear GBCA and 62 macrocyclic, respectively. At the time of surgery, gadolinium deposits were detected in 39 out of 69 (57%) tumor samples, 8 out of 13 (62%) normal brain, and 12 out of 14 (86%) necrotic specimens. Gadolinium was detected in both enhancing and non-enhancing tumors, but was greatest in gliomas with noticeable enhancement (p = 0.02). Administration of linear agents gadodiamide and gadopentetate dimeglumine resulted in significantly higher tumorgadolinium relative to macrocyclic gadoteratemeglumine (p < 0.01 and p < 0.05, respectively). Normal brain and necrosis also showed higher gadolinium after exposure to linear gadodiamide (both p < 0.05). In multivariate regression, GBCA type (linear/macrocyclic) was the most powerful predictor of tumorgadolinium retention (p < 0.001). CONCLUSION:Gadolinium can be detected in both enhancing and non-enhancing gliomas, neighboring normal brain, and necrosis. Gadolinium retention is higher after exposure to linear GBCAs compared with the macrocyclic gadoteratemeglumine.
Authors: Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Oliver Eidel; Sina Burth; Philipp Kickingereder; Sabine Heiland; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus Journal: Radiology Date: 2015-04-06 Impact factor: 11.105
Authors: Yuri Errante; Vincenzo Cirimele; Carlo Augusto Mallio; Vincenzo Di Lazzaro; Bruno Beomonte Zobel; Carlo Cosimo Quattrocchi Journal: Invest Radiol Date: 2014-10 Impact factor: 6.016
Authors: Mark C DeLano; Maria Vittoria Spampinato; Eric Y Chang; Richard G Barr; Richard J Lichtenstein; Cesare Colosimo; Josef Vymazal; Zhibo Wen; Doris D M Lin; Miles A Kirchin; Gianpaolo Pirovano Journal: J Magn Reson Imaging Date: 2021-05-20 Impact factor: 5.119
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639
Authors: Clara Guido; Clara Baldari; Gabriele Maiorano; Angela Mastronuzzi; Andrea Carai; Concetta Quintarelli; Biagio De Angelis; Barbara Cortese; Giuseppe Gigli; Ilaria Elena Palamà Journal: Diagnostics (Basel) Date: 2022-01-12